Together with efficacy data in rodents using a species specific IFNβ construct [6,12] and the fact that a limited number of RA patients express neutralizing antibodies to AAV5 [11], our findings support the progress towards a phase I clinical trial for the local treatment of arthritis in patients with RA. Here, IFNB1 is linked to Arthritis.